Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

被引：15
|
作者：
Kuboki, Y. [1 ]
Yaeger, R. [2 ]
Fakih, M. G. [3 ]
Strickler, J. H. [4 ]
Masuishi, T. [5 ]
Kim, E. J. [6 ]
Bestvina, C. M. [7 ]
Langer, C. J. [8 ]
Krauss, J. C. [9 ]
Puri, S. [10 ]
Cardona, P. [11 ]
Chan, E. [12 ]
Tran, Q. [12 ]
Hong, D. S. [13 ]
机构：
[1] Natl Canc Ctr Hosp East, Expt Therapeut & GI Oncol Dept, Kashiwa, Japan
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[3] City Hope Comprehens Canc Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
[4] Duke Univ, Dept Med, Med Ctr, Durham, NC USA
[5] Aichi Canc Ctr Hosp, Clin Oncol Dept, Nagoya, Aichi, Japan
[6] UC Davis Comprehens Canc Ctr, Hematol Oncol Internal Med, Sacramento, CA USA
[7] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL USA
[8] Univ Penn, Hematol Oncol, Philadelphia, PA USA
[9] Univ Michigan, Hematol Oncol Internal Med, Ann Arbor, MI USA
[10] Huntsman Canc Inst, Med Hematol & Oncol, Salt Lake City, UT USA
[11] Amgen Inc, Clin Pharmacol Modeling & Simulat, Thousand Oaks, CA USA
[12] Amgen Inc, Res & Dev, Thousand Oaks, CA USA
[13] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315O
引用
收藏
页码：S680 / S681
页数：2
相关论文
共 50 条
  • [1] Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
    Kuboki, Y.
    Yaeger, R.
    Fakih, M.
    Strickler, J. H.
    Masuishi, T.
    Kim, E. J-H.
    Bestvina, C. M.
    Langer, C. J.
    Krauss, J. C.
    Puri, S.
    Cardona, P.
    Chang, E. K.
    Tran, Q.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1445 - S1446
  • [2] Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer: a phase 1b trial
    Kuboki Y.
    Fakih M.
    Strickler J.
    Yaeger R.
    Masuishi T.
    Kim E.J.
    Bestvina C.M.
    Kopetz S.
    Falchook G.S.
    Langer C.
    Krauss J.
    Puri S.
    Cardona P.
    Chan E.
    Varrieur T.
    Mukundan L.
    Anderson A.
    Tran Q.
    Hong D.S.
    Nature Medicine, 2024, 30 (1) : 265 - 270
  • [3] Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
    Fakih, Marwan G.
    Salvatore, Lisa
    Esaki, Taito
    Modest, Dominik P.
    Lopez-Bravo, David P.
    Taieb, Julien
    Karamouzis, Michalis V.
    Ruiz-Garcia, Erika
    Kim, Tae-Won
    Kuboki, Yasutoshi
    Meriggi, Fausto
    Cunningham, David
    Yeh, Kun-Huei
    Chan, Emily
    Chao, Joseph
    Saportas, Yaneth
    Tran, Qui
    Cremolini, Chiara
    Pietrantonio, Filippo
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (23): : 2125 - 2139
  • [4] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
    Reactions Weekly, 2025, 2045 (1) : 6 - 6
  • [5] Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)
    Hong, David S.
    Kuboki, Yasutoshi
    Yaeger, Rona
    Strickler, John H.
    Masuishi, Toshiki
    Langer, Corey
    Shergill, Ardaman
    Kim, Edward
    Hindoyan, Antreas
    Tran, Qui
    Mukundan, Lata
    Chan, Emily
    Anderson, Abraham
    Fakih, Marwan G.
    CANCER RESEARCH, 2023, 83 (07)
  • [6] A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C-mutated colorectal cancer.
    Yaeger, Rona
    Langer, Corey J.
    Ruffinelli, Jose Carlos
    Fakih, Marwan
    Furqan, Muhammad
    Machiels, Jean-Pascal H.
    Saportas, Yaneth
    Nolte-Hippenmeyer, Jane
    Chan, Emily
    Xia, Caihong
    Masuishi, Toshiki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 128 - 128
  • [7] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
    Clarke, J. M.
    Felip, E.
    Li, B. T.
    Ruffinelli, J. C.
    Garrido, P.
    Zugazagoitia, J.
    Goldberg, S. B.
    Ramalingam, S. S.
    Victoria, I.
    Puri, S.
    Gandara, D. R.
    Varrieur, T.
    Edmonds, S.
    Palmer, K.
    Snyder, W.
    Govindan, R.
    Rybkin, I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
  • [8] Impact of Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC
    Patel, Sandip P.
    ONCOLOGY-NEW YORK, 2023, 37 (12): : 479 - 479
  • [9] Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
    Hong, David S.
    Kuboki, Yasutoshi
    Strickler, John H.
    Fakih, Marwan
    Houssiau, Helene
    Price, Timothy Jay
    Elez, Elena
    Siena, Salvatore
    Chan, Emily
    Nolte-Hippenmeyer, Jane
    Cardona, Panli
    Tran, Qui
    Masuishi, Toshiki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
    Siena, S.
    Yamaguchi, K.
    Ruffinelli Rodriguez, J. C.
    Corral de la Fuente, E.
    Kuboki, Y.
    Cremolini, C.
    Victoria Ruiz, I.
    Elez Fernandez, M. E.
    Strickler, J. H.
    Furqan, M.
    Bashir, B.
    Nduka, C.
    Hippenmeyer, J.
    Chan, E.
    Xia, C.
    Masuishi, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S429 - S430
12345